Publikationen, an denen er mitarbeitet VANESA ANDRÉS GUERRERO (18)

2023

  1. A novel osmoprotective liposomal formulation from synthetic phospholipids to reduce in vitro hyperosmolar stress in dry eye treatments

    Journal of Liposome Research, Vol. 33, Núm. 2, pp. 117-128

  2. Desarrollo de una formulación antiglaucomatosa tópica a partir de una lágrima artificial

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Long-acting hybrid microemulsion for the simultaneous treatment of glaucoma and ocular surface diseases

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost

    Ocular Surface, Vol. 29, pp. 314-330

2022

  1. Cytokine profile in tear and aqueous humor of primary open-angle patients as a prognostic factor for trabeculectomy outcome

    European Journal of Ophthalmology, Vol. 32, Núm. 5, pp. 2994-3004

  2. Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection

    International Journal of Pharmaceutics, Vol. 623

  3. Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment

    Pharmaceutics, Vol. 14, Núm. 7

  4. Nuevas terapias hipotensoras en el tratamiento del glaucoma: New hypotensive therapies in the treatment of glaucoma

    III Congreso Interdisciplinar de Jóvenes Investigadores 23 y 24 de septiembre de 2021

  5. Proinflammatory Cytokine Profile Differences between Primary Open-Angle and Pseudoexfoliative Glaucoma

    Ophthalmic research

2021

  1. Combined hyperosmolarity and inflammatory conditions in stressed human corneal epithelial cells and macrophages to evaluate osmoprotective agents as potential DED treatments

    Experimental Eye Research, Vol. 211

  2. The effect of a triple combination of bevacizumab, sodium hyaluronate and a collagen matrix implant in a trabeculectomy animal model

    Pharmaceutics, Vol. 13, Núm. 6

  3. “In vitro” hyperosmolar design in human corneal epithelial cells and inflammation in macrophages: avoiding the use of animals in the screening of ocular surface therapies

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 41-43

2018

  1. Donadores de óxido nítrico como hipotensores en glaucoma

    Archivos de la Sociedad Española de Oftalmologia, Vol. 93, Núm. 6, pp. 290-299

2017

  1. Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma

    Advances in Therapy, Vol. 34, Núm. 2, pp. 378-395

  2. Preliminary study of the differences in optic nerve head hemoglobin measures between patients with and without childhood glaucoma

    Journal of Pediatric Ophthalmology and Strabismus, Vol. 54, Núm. 6, pp. 387-394

  3. Targeting Schlemm’s Canal in the Medical Therapy of Glaucoma: Current and Future Considerations

    Advances in Therapy, Vol. 34, Núm. 5, pp. 1049-1069

2015

  1. Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology

    Journal of Controlled Release, Vol. 211, pp. 105-117

2011

  1. Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers

    Investigative Ophthalmology and Visual Science, Vol. 52, Núm. 6, pp. 3548-3556